<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879277</url>
  </required_header>
  <id_info>
    <org_study_id>DR210098</org_study_id>
    <secondary_id>2021-A01035-36</secondary_id>
    <nct_id>NCT04879277</nct_id>
  </id_info>
  <brief_title>Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria</brief_title>
  <acronym>INGRAPH</acronym>
  <official_title>Etude de l'INflammation systémique de Bas GRade Chez Les Patients Adultes Atteints de PHénylcétonurie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient suffering from phenylketonuria have chronic hyperphenylalaninemia.&#xD;
      Hyperphenylalaninemia is known to be toxic to central nervous system and cardiovascular&#xD;
      system in particular through oxydative stress.&#xD;
&#xD;
      In this context, research of low grade systemic inflammation through cytokine assay appears&#xD;
      legitimate.&#xD;
&#xD;
      The primary outcome of this study is to describe inflammation profile of patients with&#xD;
      phenylketonuria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phenylketonuria (PKU) is a metabolic hereditary disease due to lack of activity of&#xD;
      phenylalanine hydroxylase. This lack of activity whom origin is genetic, results in chronic&#xD;
      hyperphenylalaninemia, toxic to central nervous system and cardiovascular system. Without&#xD;
      treatment, PKU is responsible for mental retardation in children.&#xD;
&#xD;
      PKU is subject to systematic screening at birth and if diagnosis is confirmed a specific diet&#xD;
      controlled in phenylalanine is prescribed for infant. This diet allows a neurodevelopment as&#xD;
      closed as healthy infant. Despite this diet, neurological and systemic complications are more&#xD;
      often reported at adult age. It is therefore recommended to follow patient regularly in order&#xD;
      to search for those complications.&#xD;
&#xD;
      In a PKU murine model, it has been shown (cf references) that a low grade systematic&#xD;
      inflammation exists and was reversible after dietetic treatment using glycomacropeptide&#xD;
      (through a probiotic effect of this protein naturally phenylalanine free). Existence of this&#xD;
      low grade systematic inflammation, evaluated by plasmatic cytokine screening (TNF alpha IL2,&#xD;
      IL6, IL10, IFNgamma, IL1Alpha, IL1Beta and protein C reactive) has not been proven in humans&#xD;
      to date.&#xD;
&#xD;
      Primary outcome of this study is to characterize this low grade systemic inflammation profile&#xD;
      in patient with PKU.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Actual">August 25, 2021</completion_date>
  <primary_completion_date type="Actual">August 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One group of healthy subject and one group of patient with phenylketonuria. Primary objective is to compare inflammation profile between the two groups through cytokine assay.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of pro-inflammatory cytokines</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Plasmatic pro-inflammatory cytokine assay in PKU patients and healthy subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of CRP</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Plasmatic CRP assay in PKU patients and healthy subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of phenylalanine</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Plasmatic phenylalanine assay in PKU patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of tyrosine</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Plasma tyrosine assay in PKU patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>Healthy subject</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention, specific to the study, is to take blood samples on patients healthy volunteers.&#xD;
Healthy subject will be paired to patient with phenylketonuria according to body mass index and sex.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with phenylketonuria</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention, specific to the study, is to take blood samples on patients with phenylketonuria</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.</description>
    <arm_group_label>Healthy subject</arm_group_label>
    <arm_group_label>Patient with phenylketonuria</arm_group_label>
    <other_name>Plasmatic Cytokine and plasmatic CRP assay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (patient with PKU)&#xD;
&#xD;
          -  Age &gt;/= 18 years old&#xD;
&#xD;
          -  Phenylketonuria diagnosis&#xD;
&#xD;
          -  Fasting condition&#xD;
&#xD;
          -  Registered with a social security system&#xD;
&#xD;
          -  Patient consent&#xD;
&#xD;
        Inclusion Criteria (healthy volunteer)&#xD;
&#xD;
          -  Age &gt;/= 18 years old&#xD;
&#xD;
          -  No metabolic condition&#xD;
&#xD;
          -  Fasting condition&#xD;
&#xD;
          -  Paired to patient with phenylketonuria already included according to age, sex and BMI&#xD;
             class&#xD;
&#xD;
          -  Registered with a social security system&#xD;
&#xD;
          -  Volunteer consent&#xD;
&#xD;
        Exclusion Criteria, common to healthy volunteer and patient with phenylketonuria&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Subject to legal protection measures.&#xD;
&#xD;
          -  Chronic or acute inflammatory disease&#xD;
&#xD;
          -  Fever on inclusion&#xD;
&#xD;
          -  Undergoing anti inflammatory treatment&#xD;
&#xD;
          -  Surgery in the previous months&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Included in other therapeutic trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François MAILLOT, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical investigation center, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Service, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Solverson P, Murali SG, Brinkman AS, Nelson DW, Clayton MK, Yen CL, Ney DM. Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria. Am J Physiol Endocrinol Metab. 2012 Apr 1;302(7):E885-95. doi: 10.1152/ajpendo.00647.2011. Epub 2012 Jan 31.</citation>
    <PMID>22297302</PMID>
  </reference>
  <reference>
    <citation>van Spronsen FJ, van Wegberg AM, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Giżewska M, Huijbregts SC, Kearney S, Leuzzi V, Maillot F, Muntau AC, Trefz FK, van Rijn M, Walter JH, MacDonald A. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017 Sep;5(9):743-756. doi: 10.1016/S2213-8587(16)30320-5. Epub 2017 Jan 10. Review.</citation>
    <PMID>28082082</PMID>
  </reference>
  <reference>
    <citation>Boulet L, Besson G, Van Noolen L, Faure P; ECOPHEN Study Group, Maillot F, Corne C. Tryptophan metabolism in phenylketonuria: A French adult cohort study. J Inherit Metab Dis. 2020 Sep;43(5):944-951. doi: 10.1002/jimd.12250. Epub 2020 Jun 4.</citation>
    <PMID>32392388</PMID>
  </reference>
  <reference>
    <citation>Stroup BM, Nair N, Murali SG, Broniowska K, Rohr F, Levy HL, Ney DM. Metabolomic Markers of Essential Fatty Acids, Carnitine, and Cholesterol Metabolism in Adults and Adolescents with Phenylketonuria. J Nutr. 2018 Feb 1;148(2):194-201. doi: 10.1093/jn/nxx039.</citation>
    <PMID>29490096</PMID>
  </reference>
  <reference>
    <citation>Matalon R, Surendran S, McDonald JD, Okorodudu AO, Tyring SK, Michals-Matalon K, Harris P. Abnormal expression of genes associated with development and inflammation in the heart of mouse maternal phenylketonuria offspring. Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3):557-65.</citation>
    <PMID>16164837</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low grade inflammation</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Phenylketonuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

